The Risk of Colon Cancer in Inflammatory Bowel Disease

Ross Jones, Martin Scobey and Jianfeng Cheng*

Division of Gastroenterology, Internal Medicine, UNC School of Medicine Charlotte, Carolinas Medical Center, USA

Abstract

Inflammatory Bowel Disease (IBD) involves chronic inflammation in the patient's digestive track, leading to the development of ulcerative colitis and Crohn's disease. IBD is painful and debilitating disease that develops into life threatening risk in the long run, particularly colorectal carcinoma (CRC). As per the studies, there are 18% of chances for the IBD to develop into colorectal carcinoma after 30 years. Although IBD is contributing to only 1% of overall Colorectal Cancer cases, the mortality rate is pretty high among the colorectal cancer developed due to IBD. The present article prescribes guidelines for screening and surveillance that minimizes the risks of CRC.

Keywords: Inflammatory Bowel Disease (IBD); Colitis and crohn's disease; Colorectal cancer (CRC), Screening and surveillance

Introduction

Inflammatory Bowel Disease (IBD), in the form of Ulcerative Colitis or Crohn's Disease, is considered a high risk condition for the development of colorectal carcinoma (CRC). Previous studies, based predominantly upon patients with Ulcerative Colitis, have demonstrated an 18% chance of developing CRC after 30 years of disease [1,2]. Although IBD accounts for less than 1% of colorectal cancers diagnosed, IBD associated CRC has been shown to carry a higher mortality rate compared to CRC arising in average risk populations [3].

Although surveillance has never been shown to have a positive effect on mortality, guidelines on screening and surveillance have been established for this specific population. These current guidelines based upon expert opinion focus on the detection of dysplasia and identification of patients who will benefit from closer, more frequent endoscopic screening and surveillance. The risk for development of CRC is not uniform for all IBD patients and different patient characteristics and disease manifestations need to be taken into account. This article will review specific risk factors as they relate to CRC development in the IBD population and the current screening/therapeutic guidelines for these patients.

Colon Cancer Risk in IBD

Overall risk

Much of the data related to the epidemiology of CRC in IBD is older and largely related to UC. In addition, difficulties arise when comparing studies looking at different patient populations in terms of severity, disease location, disease extent and the time-period in question. Many early cohort studies focused on referral populations which likely had more extensive, severe disease at presentation compared to more recently published population studies. There has been wide variability in reported risk of CRC in IBD patients, ranging from almost no risk compared to general population to an incidence 60% higher than the general public, with a reported 18% cumulative chance of CRC after 30 years [1,4-6]. An early meta-analysis by Eaden et al. [2] reported an overall risk of 2% at 10 years and up to 18% at 30 years. Other studies have shown a downtrend in the overall apparent risk of developing CRC in UC patients, although one large 30-year surveillance study from the United Kingdom showed only a slightly lower rate of 15% at 30 years [5].

More recent population studies have yielded conflicting results. A recent large Danish cohort study of 47,374 patients found that there has been a general change in the relative risk for CRC development over the past 30 years [6,7]. Their data demonstrated a downward trend in the risk for CRC development in IBD patients and they postulated that these findings were likely due to the increased use of immune modulators and the newer biologic agents such as in fliximab. The relative risk (RR) of CRC was found only to be 1.07 [95% CI, 0.95-1.21]. However, the RR score was markedly increased in certain populations including patients diagnosed at age <19 years [RR of 43.8, 95% CI, 27.2-70.7] as well as those diagnosed prior to the year 1988 [RR of 1.34; 95% CI, 1.13-1.58]. As mentioned earlier, CRC risk has been much more extensively studied in UC patients compared to CD patients. Many of the recommendations for screening and surveillance are based upon UC that has been extrapolated to CD. There has been, however, one study in which the incidence of CRC has been compared in a head to head fashion between UC and CD [8]. This study demonstrated similarities in risk, age at diagnosis and overall survivability when the location, extent and duration of disease were taken into account.

Risk related to extent of disease progression

IBD involvement of the colon can, by its very nature, be localized or extensive. UC typically exhibits confluent involvement of the colon ranging from only the rectum (proctitis) to the entire colon (pancolitis). Left sided disease generally refers to disease distal to the hepatic flexure.

Crohn's colitis usually affects segments of the colon but can present as pancolitis as well. Extent of disease is usually determined endoscopically and to a lesser degree by histology [9]. Isolated proctitis carries no significant increase in CRC risk above the general population and left sided UC carries a risk intermediate to that of pan-colitis [10]. In a Swedish-cohort study [1], the RR of CRC was dependent on the extent of disease as follows: 14.8 [95%CI, 11.4-18.9] for pan-colitis, 2.8 (95%CI, 1.6-4.4) for left-sided colitis, and 1.7 (95%CI, 0.8-3.2) for proctitis. Although left-sided colitis is more favorable than pancolitis after 10-20 years, it seems to have a similar risk compared to pancolitis by the fourth decade of disease [11-13]. Crohn's colitis of at least 1/3 colon involvement assumes the same risks as listed above of pancolitis [14,15].

*Corresponding author: Jianfeng Cheng, Clinical Assistant Professor of Medicine, UNC School of Medicine Charlotte campus, Division of Gastroenterology, Department of Internal Medicine, Carolinas Medical Center, Charlotte, NC 28203, USA, Tel: 704 355-7470; Fax: 704 355-0770; E-mail: Jianfeng.cheng@carolinashealthcare.org

Risk Related to the Presence of Both IBD and Primary Sclerosing Cholangitis (PSC).

PSC and IBD are two diseases that have a strong association with one another. The prevalence of IBD has been reported as high as 60-80% in PSC patients [DDS #5]. The clinical importance of this association was highlighted by a meta-analysis by Soetikino et al. [16], who reported an almost 5-fold increase in the risk of colorectal dysplasia compared to patients with UC alone. The odds ratio (OR) for dysplasia was 4.79 (95%CI, 3.58-6.41) for dysplasia and for CRC itself was 4.09 (95%CI, 2.89-5.76). This study has been further supported by study from Sweden as well [17].

The reason for this increased risk is not fully understood. A study by Sokol et al. [18] showed that PSC-UC patients are given more 5-ASA treatment, suggesting more inflammation, which is possibly responsible for the PSC-UC association. Due to this high risk of CRC and dysplasia in PSC-UC patients, current recommendations are to begin screening all PSC patients for colorectal inflammation at the time of PSC diagnosis and to continue yearly surveillance in PSC patients with concurrent colitis. This recommendation continues even after liver transplantation for PSC after alarming results were reported in this population as well [17].

Risk related to other factors

Additional risk factors for CRC development in IBD include disease duration, earlier age of onset, family history of sporadic CRC, and persistent inflammation of the colon. Based on the meta-analysis performed by Eaden et al. [2], the risk of CRC becomes a significant concern after 10 years of disease. Disease onset should be defined as the beginning of symptoms rather than the time of actual IBD diagnosis as this will significantly decrease the amount of CRC's found at time of screening colonoscopy [19,20]. Both Eaden's meta-analysis [2] and the bulk of older studies [1,5,6] showed a relationship to disease duration. Nevertheless, disease duration is still the major factor for screening and surveillance recommendations, In regard to age of onset, the data concerning risk is conflicting. Studies by Rutter et al. [5] showed no correlation with an early age of diagnosis and more rapid progression to CRC. A retrospective study by Karvellas et al. [21], however, showed that patients diagnosed with UC prior to 40 years of age developed CRC more quickly than those diagnosed over the age of 40 years [OR 11.5; 95%CI, 2.41-20.16]. Because of the conflicting data, current screening recommendations do not factor in the age at diagnosis. A family history of sporadic colorectal cancer has been reported to be twice as likely in IBD patients with CRC compared to IBD patients without CRC. A study by Askling et al. [22] found that a positive family history of CRC translated in to a RR of 2.5 [95% CI, 1.4-4.4] for the development of CRC in patients with IBD. That RR increased to 9.2 if that relative was a first-degree relative. Relatives of patients with IBD have not been shown, however, to have an increased risk of CRC. Currently, family history is not formally noted in screening and surveillance guidelines, but may influence stratification and discussion about CRC risk in individual IBD patients.

IBD is characterized by underlying inflammation, so it would be presumed that the degree of inflammation would further increase the CRC risk in IBD. Rutter et al. [4] found that both macroscopic and microscopic changes were associated with increased risk for neoplasia, with OR of 2.5 and 5.1 respectively. The presence of histologic disease may also continue even when disease appears quiescent endoscopically [5,23,24]. In a study from Mayo Clinic, post-inflammatory polyps were shown to be associated with the development of IBD associated CRC. Another study by Rutter, further amplified this with a reported OR of 2.14 for CRC in patients with post-inflammatory polyps. Although they are not thought to possess malignant potential themselves, post-inflammatory polyps as markers of ongoing histologic inflammation appear to increase the risk of CRC [25].

Screening and surveillance recommendations

Although the degree of risk of CRC in IBD may be debated, multiple societies (AGA, ASGE etc.) currently endorse screening and surveillance programs for IBD patients. In order for a screening and surveillance strategy to be effective, patients must be made aware of the risk. The goal of IBD screening and surveillance programs is to identify the presence of dysplasia prior to the development of CRC. It should be noted; however, that colorectal dysplasia in IBD is thought to be progress along an accelerated timeline compared to that seen in sporadic CRC [26]. It is the presence of dysplasia that increases the risk of CRC and has direct implications in the patient's health. A meta-analysis of over 1225 patients found that 42% of patients with high-grade dysplasia and 19% of patients with low-grade dysplasia actually had a concurrent CRC that was not noted on their colonoscopy exam [27]. Low grade dysplasia is also concerning as noted by one review that showed 34% of patients with low grade dysplasia at initial exam, progressing to CRC at later follow-up exams [28].

Due to these concerns over dysplasia and eventual CRC development, current guidelines generally recommend initiation of screening colonoscopy 8-10 years after onset of pan-colitis and suggest considering initiating surveillance at 15 years after onset of left-sided colitis [9]. No surveillance recommendations are made for proctitis. Surveillance should begin immediately upon diagnosis of PSC in an IBD patient.

Current screening and surveillance guidelines recommend random colon biopsies every 10cm in 4 quadrants. The goal of these biopsies is to detect flat lesions that are not obvious endoscopically. These recommendations stem from a study by Rubin et al. [29], showing that 33 biopsies were needed to detect dysplasia with 90% probability, and 64 biopsies were needed to increase the probability to 95%. This is in addition to additional biopsy and endoscopic removal of any raised or abnormal appearing polyps or lesions.

Per recent AGA guidelines, the endoscopic treatment of raised lesions depends on the features of the lesion. Raised lesions containing dysplasia that are not deemed to be endoscopically resectable typically should be referred for colectomy. Endoscopic management of more polypoid lesions depends on location of the mass. If contained outside active colitis, the lesion should be removed endoscopically and surveillance continued. However, if contained within an area of active colitis, the lesion should be removed and the surrounding tissue margin biopsied to assess presence of any associated flat dysplasia. The presence of associated flat dysplasia warrants referral for colectomy. A completely removed lesion with no apparent flat lesions associated, may proceed with increased surveillance. However, any further development of dysplasia should prompt colectomy [9].

The best method for detecting these dysplastic lesions is evolving. Current U.S. societies do not advocate for or against more advanced imaging or targeting techniques to help identify dysplastic lesions. The British Gastroenterology Society [30] advocates the use of chromo endoscopy, a technique that involves spraying either Indigo carmine or methylene blue onto the colonic mucosa to help identify abnormalities in the tissue. This has been shown in multiple studies to be more effective for dysplasia detection. In a prospective study of 700 patients by Hurlstone et al. [31], chromo endoscopy identified 69 dysplastic lesions compared to only 24 that were found with conventional white

light endoscopy and random biopsies (p<0.001). Similar results have been reported by Kiesslich [32] with the use of methylene blue.

Conclusion

IBD carries an increased risk for the development of colorectal cancer. Additional risk factors to consider include disease duration, the presence of PSC, the age at onset, the extent of affected colon and a positive family history of CRC. Per guideline recommendations, patients with IBD involving the colon should be considered for CRC screening and surveillance after 8 years of disease with modifications based upon the presence or absence of other risk factors which may help to tailor individual approaches to CRC risk

References

1. Ekbom A, Helmick C, Zack M, Adami HO (1990) Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 323: 1228-1233.

2. Eaden JA, Abrams KR, Mayberry JF (2001) The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48: 526-535.

3. Richards ME, Rickert RR, Nance FC (1989) Crohn's disease-associated carcinoma. A poorly recognized complication of inflammatory bowel disease. Ann Surg 209: 764-773.

4. Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, et al. (2004) Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126: 451-459.

5. Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, et al. (2006) Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 130: 1030-1038.

6. Jess T, Simonsen J, Jørgensen KT, Pedersen BV, Nielsen NM, et al. (2012) Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 143: 375-381.

7. Söderlund S, Brandt L, Lapidus A, Karlén P, Broström O, et al. (2009) Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology 136: 1561-1567.

8. Choi PM, Zelig MP (1994) Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut 35: 950-954.

9. Farraye FA, Odze RD, Eaden J, Itzkowitz SH, McCabe RP, et al. (2010) AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 138: 738-745.

10. Levin B (1992) Inflammatory bowel disease and colon cancer. Cancer 70: 1313-1316.

11. Greenstein AJ, Sachar DB, Smith H, Pucillo A, Papatestas AE, et al. (1979) Cancer in universal and left-sided ulcerative colitis: factors determining risk. Gastroenterology 77: 290-294.

12. Gyde SN, Prior P, Allan RN, Stevens A, Jewell DP, et al. (1988) Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut 29: 206-217.

13. Sugita A, Sachar DB, Bodian C, Ribeiro MB, Aufses AH Jr, et al. (1991) Colorectal cancer in ulcerative colitis. Influence of anatomical extent and age at onset on colitis-cancer interval. Gut 32: 167-169.

14. Friedman S, Rubin PH, Bodian C, Harpaz N, Present DH (2008) Screening and surveillance colonoscopy in chronic Crohn's colitis: results of a surveillance program spanning 25 years. Clin Gastroenterol Hepatol 6: 993-998.

15. Chapman R, Fevery J, Kalloo A (2009) Diagnosis and management of primary sclerosing cholangitis. Hepatology 50: 808-814.

16. Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO (2002) Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 56: 48-54.

17. Broomé U, Löfberg R, Veress B, Eriksson LS (1995) Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology 22: 1404-1408.

18. Sokol H, Cosnes J, Chazouilleres O, Beaugerie L, Tiret E, et al. (2008) Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. World J Gastroenterol 14: 3497-3503.

19. Vera A, Gunson BK, Ussatoff V, Nightingale P, Candinas D, et al. (2003) Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis. Transplantation 75: 1983-1988.

20. Lutgens MW, Vleggaar FP, Schipper ME, Stokkers PC, van der Woude CJ, et al. (2008) High frequency of early colorectal cancer in inflammatory bowel disease. Gut 57: 1246-1251.

21. Karvellas CJ, Fedorak RN, Hanson J, Wong CK (2007) Increased risk of colorectal cancer in ulcerative colitis patients diagnosed after 40 years of age. Can J Gastroenterol 21: 443-446.

22. Askling J, Dickman PW, Karlén P, Broström O, Lapidus A, et al. (2001) Colorectal cancer rates among first-degree relatives of patients with inflammatory bowel disease: a population-based cohort study. Lancet 357: 262-266.

23. Lakatos L, Mester G, Erdelyi Z, David G, Pandur T, et al. (2006) Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis 12: 205-211.

24. Smith MP, Loe RH (1965) Sclerosing Cholangitis; Review of Recent Case Reports and Associated Diseases and Four New Cases. Am J Surg 110: 239-246.

25. Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, et al. (2004) Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut 53: 1813-1816.

26. Xie J, Itzkowitz SH (2008) Cancer in inflammatory bowel disease. World J Gastroenterol 14: 378-389.

27. Bernstein CN, Shanahan F, Weinstein WM (1994) Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet 343: 71-74.

28. Gorfine SR, Bauer JJ, Harris MT, Kreel I (2000) Dysplasia complicating chronic ulcerative colitis: is immediate colectomy warranted? Dis Colon Rectum 43: 1575-1581.

29. Rubin CE, Haggitt RC, Burmer GC, Brentnall TA, Stevens AC, et al. (1992) DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 103: 1611-1620.

30. Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJ, et al. (2010) Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 59: 666-689.

31. Hurlstone DP, Sanders DS, Lobo AJ, McAlindon ME, Cross SS (2005) Indigo carmine-assisted high-magnification chromoscopic colonoscopy for the detection and characterization of intraepithelial neoplasia in ulcerative colitis: a prospective evaluation. Endoscopy 37:1186-1192.

32. Kiesslich R, Fritsch J, Holtmann M, Koehler HH, Stolte M, et al. (2003) Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 124: 880-888.